In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.68 a new company low.

Within Biotechnology & Pharmaceuticals industry 119 other companies have achieved higher Quick Ratio than Vaxcyte Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 230 to 2340.

Explain Quick Ratio?
How much Cash & cash equivalents PCVX�s has?
What are PCVX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PCVX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	326.35 %	92.77 %	27.35 %	47.54 %	62.81 %
Y / Y Cash & cash equivalent Change	-40.28 %	3.91 %	-10.66 %	-21.52 %	-78.88 %
Quick Ratio MRQ	0.68	17.15	12.49	18.95	4.82
PCVX's Total Ranking	# 2340	# 230	# 88	# 126	#
Seq. Current Liabilities Change	167.81 %	-18.95 %	38.37 %	41.94 %	21.09 %
Seq. Cash & cash equivalent Change	-89.45 %	11.29 %	-8.79 %	457.9 %	-81.65 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 120
Healthcare Sector	# 700
Overall Market	# 2340

Quick Ratio Statistics
High	Average	Low
62.04	20.88	0.68
(Jun 30 2020)		(Jun 30 2026)

Financial Statements
Vaxcyte Inc 's Current Liabilities	$ 271 Millions	Visit PCVX's Balance sheet
Vaxcyte Inc 's Cash & cash equivalent	$ 183 Millions	Visit PCVX's Balance sheet
Source of PCVX's Sales		Visit PCVX's Sales by Geography

Cumulative Vaxcyte Inc 's Quick Ratio

PCVX's Quick Ratio for the trailling 12 Months

PCVX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	113.36 %	51.49 %	19.49 %	15.07 %	14.24 %
Y / Y Cash & cash equivalent TTM Growth	-12.08 %	-24.62 %	-23.54 %	-12.31 %	11.75 %
Quick Ratio TTM	8.83	13.98	15.84	17.85	21.44
Total Ranking TTM	# 3958	# 3536	# 1472	# 2358	#
Seq. Current Liabilities TTM Growth	54.61 %	14.71 %	8.81 %	10.56 %	9.78 %
Seq. Cash & cash equivalent TTM Growth	-2.32 %	1.25 %	-3.43 %	-7.94 %	-16.25 %

Quick ratio ranking by company, industry and sector >> Back to PCVX Financial Strength Comparisons >> Go to Compare PCVX Quick Ratio to its Competitors

News about Vaxcyte Inc Quick Ratio

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte, Inc., a clinical-stage vaccine innovation company specializing in high-fidelity vaccines against bacterial diseases, has recently announced the initiation of an underwritten public offering of its common stock and pre-funded warrants. With a mission to safeguard humanity from the consequences of bacterial diseases, Vaxcyte aims to raise capital through this offering to further fuel its groundbreaking research and development efforts.
The company plans to offer all shares of common stock and pre-funded warrants in this public offering. In addition, Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total shares of common stock offered, including those underlying the pre-funded warrants. However, the completion, size, and terms of the offering are subject to market conditions and other variables, and therefore, are not guaranteed.

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $271.28 millions, cumulative Quick Ratio decreased to 8.83 above the PCVX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Vaxcyte Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3536 to 3958.

Explain Quick Ratio?
How much Cash & cash equivalents PCVX�s has?
What are PCVX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 893
Within the Market	# 3958

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.29	5.71	0.98
(Dec 31 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Kymera Therapeutics Inc	1.75	$ 124.477 Millions	$ 71.326 Millions
Biocryst Pharmaceuticals Inc	1.69	$ 353.279 Millions	$ 208.846 Millions
Coherus Oncology inc	1.69	$ 127.683 Millions	$ 75.510 Millions
Bio techne Corp	1.62	$ 264.712 Millions	$ 163.700 Millions
Atara Biotherapeutics Inc	1.45	$ 9.900 Millions	$ 6.847 Millions
Twist Bioscience Corporation	1.39	$ 166.839 Millions	$ 120.255 Millions
Neumora Therapeutics Inc	1.34	$ 116.834 Millions	$ 87.478 Millions
Calidi Biotherapeutics Inc	1.33	$ 4.290 Millions	$ 3.237 Millions
Passage Bio Inc	1.17	$ 24.155 Millions	$ 20.719 Millions
Mink Therapeutics Inc	1.16	$ 8.807 Millions	$ 7.569 Millions
Amgen Inc	1.07	$ 27,404.000 Millions	$ 25,502.000 Millions
Aligos Therapeutics Inc	1.07	$ 30.381 Millions	$ 28.343 Millions
Vaxart Inc	1.05	$ 77.058 Millions	$ 73.108 Millions
Iovance Biotherapeutics inc	1.04	$ 110.768 Millions	$ 106.848 Millions
Liminatus Pharma Inc	0.99	$ 3.017 Millions	$ 3.040 Millions
Elutia Inc	0.95	$ 19.896 Millions	$ 21.045 Millions
Jasper Therapeutics Inc	0.93	$ 7.314 Millions	$ 7.845 Millions
Protalix Biotherapeutics inc	0.90	$ 28.140 Millions	$ 31.391 Millions
Vivosim Labs Inc	0.88	$ 1.670 Millions	$ 1.893 Millions
Senti Biosciences Holdings Inc	0.83	$ 13.124 Millions	$ 15.765 Millions
Pelthos Therapeutics Inc	0.78	$ 24.776 Millions	$ 31.959 Millions
Ocugen Inc	0.75	$ 100.051 Millions	$ 133.080 Millions
Sab Biotherapeutics Inc	0.71	$ 8.267 Millions	$ 11.705 Millions
Vaxcyte Inc	0.68	$ 183.190 Millions	$ 271.277 Millions
Halozyme Therapeutics Inc	0.61	$ 231.081 Millions	$ 375.965 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions

Date modified: 2026-09-08T21:31:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.